Intrahepatic mitomycin C as a salvage treatment for patients with hepatic metastases from colorectal carcinoma.
Sixty-four evaluable patients with hepatic metastases from colorectal carcinoma, who did not have evidence of extrahepatic disease, were treated with intrahepatic (IH) mitomycin C (M) after disease progression or intolerance to treatment with IH fluorodeoxyuridine (FUDR). Eleven patients (17%) had a partial response (PR) to IH M and ten (16%) patients had stable disease. Patients who responded to IH FUDR were more likely to respond to IH M when compared with those who progressed on IH FUDR (47% versus 13%, respectively; P = 0.013). Those who were switched to IH M because of hepatotoxicity on IH FUDR also were more likely to respond to IH M than those who were switched because of progression on IH FUDR (75% versus 27%, respectively; P = 0.022). Baseline laboratory values, the percent of tumorous liver involvement, prior history of systemic chemotherapy, and the interval from diagnosis to initiation of IH M did not help predict response. Toxicity was mild and well tolerated. The overall median survival time of the 64 evaluable patients was 9.0 months from the start of IH M therapy. We conclude that IH M has some salvage benefit in patients with hepatic metastases.
Schneider
A
A
Department of Medicine, Memorial Sloan-Kettering Cancer Center, Cornell University Medical College, New York, NY 10021.
Kemeny
N
N
Chapman
D
D
Niedzwiecki
D
D
Oderman
P
P
D015179:Colorectal Neoplasms; D005260:Female; D005467:Floxuridine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007958:Leukocyte Count / Q000187:drug effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D008297:Male; D016685:Mitomycin; D008937:Mitomycins; D010976:Platelet Count / Q000187:drug effects; D012074:Remission Induction
D008937:Mitomycins; D005467:Floxuridine; D016685:Mitomycin